Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of VH5356136 in Healthy Adults
NCT07822477Phase 1Not yet recruiting
- Sponsor
- ViiV Healthcare
- Start
- Nov 2026
- Primary completion
- May 2029
01
Overview
Phase 1, randomised, double-blind trial of VH5356136 Formulation 1 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by ViiV Healthcare. Primary endpoints: Number of participants with drug-related adverse events at Month 18, Number of participants with Grade 2 to Grade 5 AEs at Month 18 and 9 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
VH5356136 Formulation 1
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07822477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07822477.